Protecting the heart.
EPAC1
cancer biology
cancer survivorship
cardiotoxicity
cell biology
doxorubicin
human
mouse
rat
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
06 09 2023
06 09 2023
Historique:
medline:
7
9
2023
pubmed:
6
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
Blocking a protein known as EPAC1 may prevent the development of heart-related side effects caused by a chemotherapy drug.
Identifiants
pubmed: 37672034
doi: 10.7554/eLife.91831
pii: 91831
pmc: PMC10482425
doi:
pii:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2023, Inglis and Mangoni.
Déclaration de conflit d'intérêts
JI, AM No competing interests declared
Références
J Clin Oncol. 2012 Nov 1;30(31):3792-9
pubmed: 22987084
J Natl Cancer Inst. 2015 Nov 23;108(4):
pubmed: 26598513
Lancet. 2022 Apr 16;399(10334):1537-1550
pubmed: 35430021
Elife. 2023 Aug 08;12:
pubmed: 37551870
Ann Oncol. 2003 Feb;14(2):277-81
pubmed: 12562656
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
J Clin Oncol. 1997 Apr;15(4):1318-32
pubmed: 9193323
Cardiovasc Res. 2019 Jan 1;115(1):94-106
pubmed: 30016400
Compr Physiol. 2015 Jul 1;5(3):1517-40
pubmed: 26140726